This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Carbamazepine, mitotane, phenytoin, phenobarbital, primidone, rifabutin, rifampin, and St John's Wort may change the way your liver processes ponatinib and regorafenib.
What might happen:
The amount of ponatinib may decrease and it may not work as well.The amount of regorafenib in your blood may increase. You could notice an increase in side effects such as high blood pressure, diarrhea, hand-foot skin reaction, or bleeding.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want you to stop taking St. John's Wort or may monitor you more closely while you are taking carbamazepine, phenytoin, rifampin, phenobarbital or St. John's Wort with regorafenib.If you notice an increase in side effects from your regorafenib, contact your healthcare professional. Your doctor may want to decrease the dose or stop your regorafenib for some time.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Iclusig (ponatinib) US prescribing information. ARIAD Pharmaceuticals Inc. December, 2013.
2.FDA. Drug Approval Package: Stivarga (regorafenib) Tablets, Application:203085, Clinical Pharmacology Review. accessed at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000Clin PharmR.pdf approval 09/27/2012.
3.Stivarga (regorafenib) US prescribing information. Bayer HealthCare Pharmaceuticals, Inc. May, 2013.
4.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
5.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..